Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Downregulation of Sprr1a Contributes to the Pathobiology of Sickle Cell Disease

Donovan A Argueta, BSc, Anupam Aich, PhD, Jianxun Lei, PhD, Sergei Nekhai, PhD, Tatiana Ammosova, PhD, Xionghao Lin, PhD, Anindya Bagchi, PhD, Kalpna Gupta, PhD

Blood (2019) 134 (Supplement_1): 75.

https://doi.org/10.1182/blood-2019-129004

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Resolution of Intractable Leg Ulcers Associated with Antiphospholipid Syndrome (APS) with Prophylactic Dose of Aspirin (ASA) and Enoxaparin: A Case Report

Carlos Dobler, Larissa A Szeyko, MD, Mark M Landeros, MD, Carmen P Arango, MD, Luis S Noble, MD, Sheeba Varughese Tano, DO, Juan Herrada, MD

Blood (2018) 132 (Supplement 1): 5071.

https://doi.org/10.1182/blood-2018-99-110752

Published: 2018

Journal Articles

Id3 Is Essential for Mediating Ezh2-Regulated Persistence of Alloreactive T Cells in Gvhd Target Tissues in Mice

Shan He, PhD, Yuanyuan Tian, Yongnian Liu, Ying Wang, Bruce Blazar, MD, Ximi K Wang, Ran Reshef, MD, Yi Zhang, MD

Blood (2017) 130 (Supplement 1): 210.

https://doi.org/10.1182/blood.V130.Suppl_1.210.210

Published: 2017

Journal Articles

Leukocyte Adhesion Deficiency-I (LAD-I): A Comprehensive Review of Published Cases

Sanchali Kasbekar, PharmD, Juan Bueren, PhD, Adrian J Thrasher, MD PhD FMedSci, Donald B Kohn, MD, Julian Sevilla, MD PhD, Jonathan D Schwartz, MD, Elena Almarza, PhD

Blood (2017) 130 (Supplement 1): 4821.

https://doi.org/10.1182/blood.V130.Suppl_1.4821.4821

Published: 2017

Journal Articles

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Farid Boulad, MD, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Danielle Guarneri, June Greenberg, RN, Caterina Minniti, MD, Sylvie wiener Fedus, Fabiana Perna, MD, Xiuyan Wang, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD, Patricia Shi, MD

Blood (2017) 130 (Supplement 1): 3531.

https://doi.org/10.1182/blood.V130.Suppl_1.3531.3531

Published: 2017

Journal Articles

Pathophysiologic Implications of Type-2 Phosphatidylserine-Positive Erythrocytes in Hemoglobin SS Disease (sickle cell anemia) and β-Thalassemia

Yamaja Setty, PhD, Suhita Gayen-Betal, PhD, Marie Stuart, MD

Blood (2017) 130 (Supplement 1): 3521.

https://doi.org/10.1182/blood.V130.Suppl_1.3521.3521

Published: 2017

Journal Articles

Knock-in of Dnmt3a R878H Recapitulates Human Acute Myeloid Leukemia Harboring DNMT3A Mutation and Is Highly Responsive to mTOR Inhibitor Rapamycin

Yujun Dai, Yueying Wang, Jinyan Huang, Li Xia, Xiaodong Shi, Sai-Juan Chen, Zhu Chen

Blood (2016) 128 (22): 2836.

https://doi.org/10.1182/blood.V128.22.2836.2836

Published: 2016

Journal Articles

Hemophagocytic Lymphohistiocytosis Associated with NK Cell Dysfunction and Disseminated Herpesvirus Infection in GATA2 Deficiency/Monomac Syndrome

Michael A. Spinner, MD, Camila Odio, B.S., Katherine R. Calvo, MD, PhD, Amy P Hsu, B.A., Christa S. Zerbe, MD, Jennifer Cuellar-Rodriguez, MD, Jennifer P. Ker, MD, Charles J. Stoudenmire, MD, Oluwole Fadare, MD, Arunima Ghosh, MD,PhD, Emily M. Mace, PhD, Jordan S. Orange, MD, PhD, Dennis D. Hickstein, MD, Steven M. Holland, MD

Blood (2014) 124 (21): 4978.

https://doi.org/10.1182/blood.V124.21.4978.4978

Published: 2014

Journal Articles

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Annette E Hay, MB ChB, Alli Murugesan, PhD, Ashley M. DiPasquale, BSc, Tom Kouroukis, MD MSc, FRCPC, Irwindeep Sandhu, MD FRCPC, Vishal Kukreti, MD, Nizar J Bahlis, MD, Johan Lategan, MD, Donna E. Reece, MD, John F. Lyons, PhD, Joana Sederias, MSc, Jean Powers, MSc, Hao Xu, MSc, Lesley K. Seymour, MD PhD FRCP (C), Anthony Reiman, MD

Blood (2014) 124 (21): 5734.

https://doi.org/10.1182/blood.V124.21.5734.5734

Published: 2014

Journal Articles

IL-22 Is Critical To The Pathogenesis Of Cutaneous Gvhd Mediated By Th17 Cells

Hemamalini Bommiasamy, Ph.D., Laura Ott, Ph.D., Shelly West, B.S., LeShara M Fulton, Ph.D., Angela Panoskaltsis-Mortari, Bruce R Blazar, MD, Lynette Fouser, PhD, Jonathan Serody, MD

Blood (2013) 122 (21): 4482.

https://doi.org/10.1182/blood.V122.21.4482.4482

Published: 2013

Journal Articles

CD8α + Jagged2 high CD11b high Regulatory Dendritic Cells Prevent Acute Gvhd

Jianyu Weng, M.D., Xin Huang, Ping Wu, Peilong Lai, Yueying Li, M.D., Lin Xu, M.D., Suxia Geng, Xin Du, MD

Blood (2013) 122 (21): 5428.

https://doi.org/10.1182/blood.V122.21.5428.5428

Published: 2013

Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 1623.

https://doi.org/10.1182/blood.V120.21.1623.1623

Published: 2012

Journal Articles

Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis

Pablo Bartolucci, Carlo Brugnara, Armando Teixeira-Pinto, Serge Pissard, Kamran Moradkhani, Hélène Jouault, Frederic Galacteros

Blood (2012) 120 (15): 3136–3141.

https://doi.org/10.1182/blood-2012-04-424184

Published: 2012

Journal Articles

Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey

Blood (2012) 119 (25): 5996–6004.

https://doi.org/10.1182/blood-2011-12-396028

Published: 2012

Includes: Supplemental data

Journal Articles

Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea

Blood (2011) 118 (21): 5157.

https://doi.org/10.1182/blood.V118.21.5157.5157

Published: 2011

Journal Articles

Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd,

Peilong Lai, Jianyu Weng, Chenwei Luo, Rong Guo, Zesheng Lu, Suxia Geng, Xin Du, PhD, Suijing Wu

Blood (2011) 118 (21): 4086.

https://doi.org/10.1182/blood.V118.21.4086.4086

Published: 2011

Journal Articles

Organ-Specific Protection from CD8 + T Cell-Mediated Acute Skin GVHD by Bortezomib Administration Correlates with Decreased IL-6.

Kai Sun, MD, Gail Sckisel, Julia Tietze, MD, Minghui Li, PhD, Thomas Sayers, PhD, Bruce R. Blazar, MD, William J. Murphy, PhD

Blood (2010) 116 (21): 3735.

https://doi.org/10.1182/blood.V116.21.3735.3735

Published: 2010

Journal Articles

Treatment of a Patient with Refractory Non-Langerhans-Cell-Histiocytosis with the Tyrosine Kinase Inhibitor Sorafenib: Clinical and Genetic Implications

Andreas Viardot, MD, Frank Stegelmann, MD, Thorsten Zenz, MD, Peter Möller, MD, Konstanze Döhner, MD

Blood (2010) 116 (21): 4715.

https://doi.org/10.1182/blood.V116.21.4715.4715

Published: 2010

Journal Articles

Novel Anti-Fibrotic Therapies for Experimental Chronic Graft-Versus-Host Disease.

Bernd M. Spriewald, MD, Pawel Zerr, MSc, Alfiya Akhmetshina, PhD, Andreas Mackensen, MD, Georg Schett, MD, Joerg H.W. Distler, MD

Blood (2009) 114 (22): 4490.

https://doi.org/10.1182/blood.V114.22.4490.4490

Published: 2009

NARROW

Downregulation of Sprr1a Contributes to the Pathobiology of Sickle Cell Disease

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Resolution of Intractable Leg Ulcers Associated with Antiphospholipid Syndrome (APS) with Prophylactic Dose of Aspirin (ASA) and Enoxaparin: A Case Report

Id3 Is Essential for Mediating Ezh2-Regulated Persistence of Alloreactive T Cells in Gvhd Target Tissues in Mice

Leukocyte Adhesion Deficiency-I (LAD-I): A Comprehensive Review of Published Cases

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease

Pathophysiologic Implications of Type-2 Phosphatidylserine-Positive Erythrocytes in Hemoglobin SS Disease (sickle cell anemia) and β-Thalassemia

Knock-in of Dnmt3a R878H Recapitulates Human Acute Myeloid Leukemia Harboring DNMT3A Mutation and Is Highly Responsive to mTOR Inhibitor Rapamycin

Hemophagocytic Lymphohistiocytosis Associated with NK Cell Dysfunction and Disseminated Herpesvirus Infection in GATA2 Deficiency/Monomac Syndrome

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

IL-22 Is Critical To The Pathogenesis Of Cutaneous Gvhd Mediated By Th17 Cells

CD8α + Jagged2 high CD11b high Regulatory Dendritic Cells Prevent Acute Gvhd

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis

Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey

Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea

Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd,

Organ-Specific Protection from CD8 + T Cell-Mediated Acute Skin GVHD by Bortezomib Administration Correlates with Decreased IL-6.

Treatment of a Patient with Refractory Non-Langerhans-Cell-Histiocytosis with the Tyrosine Kinase Inhibitor Sorafenib: Clinical and Genetic Implications

Novel Anti-Fibrotic Therapies for Experimental Chronic Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only